PHIO - Koefisien bali modal nimbang wutah RXi Pharmaceuticals

A high barrier to entry is driven by complex patent protection for gene silencing. The P/E to growth ratio exhibits volatility, where the 0.00 metric determines this level. Logistics risks from Asia are weighing on liquidity, while a lack of revenue coupled with high testing costs is depleting the reserves of Phio Pharmaceuticals (PHIO), creating severe cash flow pressure.

Phio Pharmaceuticals focuses on niche RNA interference developments to combat cancer. This ratio compares the market value of earnings with their growth rate to determine the fairness of the current price. Values below one signal that the asset is undervalued relative to its expansion. For small-cap biotechs, this is a critical marker of potential explosive growth. By analyzing the P/E ratio relative to earnings growth rates, an investor identifies entry points into undervalued technology assets.